An early prognostic marker for determining disease severity in acute cholangitis: CRP/albumin ratio

Year 2024, Volume: 3 Issue: 1, 331 - 337, 29.03.2024

Sema Nur Arasan , Osman İnan , Enes Seyda Şahiner , Aziz Surel , Emin Altıparmak , Oğuzhan Zengin , İhsan Ateş

Abstract

Introductıon: This study was undertaken to investigate the importance of the CRP/albumin ratio (CAR) as an early prognostic marker for determining disease severity in acute cholangitis.
Methods: A total of 366 patients aged >18 years diagnosed with acute cholangitis were included in the study. Acute cholangitis severity was determined according to the 2018 Tokyo criteria.
Results: The study population consisted of 49.2% patients with mild, 24.6% moderate, and 26.2% severe acute cholangitis. The cut-off CAR value for predicting moderate risk compared to the mild risk group was found to be >1 with 73.3% sensitivity and 76.7% specificity (AUC±SE: 0.785±0.03; +PV: 61.1%, -PV: 85.2%; p<0.001). The CAR cut-off value for predicting severe risk compared to the moderate risk group was found to be >2.9 with 71.9% sensitivity and 71.1% specificity (AUC±SE: 0.788±0.03; +PV: 72.6%, -PV: 70.3%; p<0.001). The CAR cut-off value for predicting admission to the intensive care unit (ICU) was >2.5 with 77.4% sensitivity and 74.6% specificity (AUC±SE: 0.803±0.03; +PV: 43.1%, -PV: 90.1%; p<0.001). The CAR cut-off value for predicting mortality was >2.8 with 100% sensitivity and 74.9% specificity (AUC±SE: 0.890±0.03; +PV: 19.5%, -PV: 100%; p<0.001). Compared to its components, the CAR was found to exhibit superior diagnostic performance in predicting moderate or severe risk, ICU admission, and mortality.
Conclusion: We found that the CAR is a good prognostic marker in determining the severity of acute cholangitis in the early period.

Keywords

Choledocholithiasis, Cholestasis, Cholangitis, Inflammation, Tokyo guidelines

References

• 1. Sulzer, J.K. & Ocuin, L.M. Cholangitis: causes, diagnosis, and management. Surgical Clinics 99, 175-184 (2019).
• 2. Endo, I., Takada, T., Hwang, T.L., Akazawa, K., Mori, R., Miura, F. et al. Optimal treatment strategy for acute cholecystitis based on predictive factors: Japan‐Taiwan multicenter cohort study. Journal of Hepato‐Biliary‐Pancreatic Sciences 24, 346-361 (2017).
• 3. Miura, F., Takada, T., Strasberg, S.M., Solomkin, J.S., Pitt, H.A., Gouma, D.J. et al. TG13 flowchart for the management of acute cholangitis and cholecystitis. Journal of hepato-biliary-pancreatic sciences 20, 47-54 (2013).
• 4. Kiriyama, S., Kozaka, K., Takada, T., Strasberg, S.M., Pitt, H.A., Gabata, T. et al. Tokyo Guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). Journal of Hepato‐Biliary‐Pancreatic Sciences 25, 17-30 (2018).
• 5. Kaplan M, Duzenli T, Tanoglu A, Cakir Guney B, Onal Tastan Y, Bicer HS. Presepsin:albumin ratio and C-reactive protein:albumin ratio as novel sepsis-based prognostic scores : A retrospective study. Wien Klin Wochenschr. 2020 Apr;132(7-8):182-187. doi: 10.1007/s00508-020-01618-9. Epub 2020 Feb 14. PMID: 32060723.
• 6. Kaplan, M., Ates, I., Akpinar, M.Y., Yuksel, M., Kuzu, U.B., Kacar, S. et al. Predictive value of C-reactive protein/albumin ratio in acute pancreatitis. Hepatobiliary & Pancreatic Diseases International 16, 424-430 (2017).
• 7. Kinoshita, A., Onoda, H., Imai, N., Iwaku, A., Oishi, M., Tanaka, K. et al. The C-reactive protein/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Annals of surgical oncology 22, 803-810 (2015).
• 8. Kiyak M, Tanoglu A. Comparison of the Efficacy of Balthazar Score and C-Reactive Protein-Albumin Ratio for Determination of Acute Pancreatitis Severity. Curr Health Sci J. 2022 Jan-Mar;48(1):81-87. doi: 10.12865/CHSJ.48.01.12. Epub 2022 Mar 31. PMID: 35911938; PMCID: PMC9289588.
• 9. Qin, G., Tu, J., Liu, L., Luo, L., Wu, J., Tao, L. et al. Serum albumin and C-reactive protein/albumin ratio are useful biomarkers of Crohn’s disease activity. Medical science monitor 22, 4393-4400 (2016).
• 10. Kiriyama, S., Takada, T., Strasberg, S.M., Solomkin, J.S., Mayumi, T., Pitt, H.A. et al. TG13 guidelines for diagnosis and severity grading of acute cholangitis (with videos). Journal of hepato-biliary-pancreatic sciences 20, 24-34 (2013).
• 11. Sayar, S., Kurbuz, K., Kahraman, R., Caliskan, Z., Atalay, R., Ozturk, O. et al. A practical marker to determining acute severe ulcerative colitis: CRP/albumin ratio. Northern clinics of Istanbul 7, 49 (2020).
• 12. Liu, Z., Shi, H. & Chen, L. Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis. BMC cancer 19, 1-9 (2019).
• 13. Mocellin, M.C., Pastore e Silva, J.d.A., Camargo, C.d.Q., Fabre, M.E.d.S., Gevaerd, S., Naliwaiko, K. et al. Fish oil decreases C-reactive protein/albumin ratio improving nutritional prognosis and plasma fatty acid profile in colorectal cancer patients. Lipids 48, 879-888 (2013).
• 14. Mao, M., Wei, X., Sheng, H., Chi, P., Liu, Y., Huang, X. et al. C‑reactive protein/albumin and neutrophil/lymphocyte ratios and their combination predict overall survival in patients with gastric cancer. Oncology letters 14, 7417-7424 (2017).
• 15. Yasukawa, K., Shimizu, A., Motoyama, H., Kubota, K., Notake, T., Fukushima, K. et al. Preoperative C‐reactive protein‐to‐albumin ratio predicts long‐term outcomes in extrahepatic cholangiocarcinoma patients. Journal of surgical oncology 122, 1094-1105 (2020).
• 16. Hamano, K., Noguchi, O., Matsumoto, Y., Watabe, T., Numata, M., Yosioka, A. et al. Usefulness of procalcitonin for severity assessment in patients with acute cholangitis. Clinical laboratory 59, 177-183 (2013).
• 17. Shinya, S., Sasaki, T., Yamashita, Y., Kato, D., Yamashita, K., Nakashima, R. et al. Procalcitonin as a useful biomarker for determining the need to perform emergency biliary drainage in cases of acute cholangitis. Journal of Hepato‐Biliary‐Pancreatic Sciences 21, 777-785 (2014).
• 18. Umefune, G., Kogure, H., Hamada, T., Isayama, H., Ishigaki, K., Takagi, K. et al. Procalcitonin is a useful biomarker to predict severe acute cholangitis: a single-center prospective study. Journal of Gastroenterology 52, 734-745 (2017).
• 19. Lyu, Y., HE, J., Wang, B., XU, Y., DU, W. & Cheng, Y. The role of procalcitonin in patients with different severity grades of acute cholangitis. Chinese Journal of Hepatobiliary Surgery, 428-430 (2014).
• 20. Lin, J., Sun, H., Li, J., Zheng, Y., Shao, C., Zhang, Y.H. et al. Role of Presepsin for the Assessment of Acute Cholangitis Severity. Clinical Laboratory 62, 679-687 (2016).